POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer

Gynecologic Oncology

Volumn 132, Issue 2, 2014, Pages 334-342

  Karlan, Beth Y ^a   Dering, Judy ^b   Walsh, Christine ^a   Orsulic, Sandra ^a   Lester, Jenny ^a   Anderson, Lee A ^b   Ginther, Charles L ^b   Fejzo, Marlena ^b   Slamon, Dennis ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Molecular profiling; Ovarian cancer; Tumor microenvironment

Indexed keywords

MOLECULAR PROFILING; OVARIAN CANCER; TUMOR MICROENVIRONMENT;

CELL ADHESION MOLECULES; CYSTADENOCARCINOMA, SEROUS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA;

EID: 84894081053     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.12.021     Document Type: Article

References (46)

1. World Health Organization Most frequent cancers: women GLOBOCAN 2008 2008 International Agency for Research on Cancer [Available at: http://globocan. iarc.fr/factsheets/populations/factsheet.asp?uno=900, Accessed September 11, 2013]
2. S.S. Buys, E. Partridge, A. Black, C.C. Johnson, L. Lamerato, and C. Isaacs et al. Effect of screening on ovarian cancer mortality JAMA 305 2011 2295 2303
3. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
4. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
5. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
6. M.A. Bookman, M.F. Brady, W.P. McGuire, P.G. Harper, D.S. Alberts, and M. Friedlander et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 2009 1419 1425
7. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
8. W. Huang da, B.T. Sherman, and R.A. Lempicki Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists Nucleic Acids Res 37 2009 1 13
9. W. Huang da, B.T. Sherman, and R.A. Lempicki Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat Protoc 4 2009 44 57
10. B. Gyorffy, A. Lanczky, and Z. Szallasi Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients Endocr Relat Cancer 19 2012 197 208
11. K. Horiuchi, N. Amizuka, S. Takeshita, H. Takamatsu, M. Katsuura, and H. Ozawa et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta J Bone Miner Res 14 1999 1239 1249
12. L. Gillan, D. Matei, D.A. Fishman, C.S. Gerbin, B.Y. Karlan, and D.D. Chang Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility Cancer Res 62 2002 5358 5364
13. S. Bao, G. Ouyang, X. Bai, Z. Huang, C. Ma, and M. Liu et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway Cancer Cell 5 2004 329 339
14. Y. Kudo, I. Ogawa, S. Kitajima, M. Kitagawa, H. Kawai, and P.M. Gaffney et al. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer Cancer Res 66 2006 6928 6935
15. M. Zhu, M.S. Fejzo, L. Anderson, J. Dering, C. Ginther, and L. Ramos et al. Periostin promotes ovarian cancer angiogenesis and metastasis Gynecol Oncol 119 2010 337 344
16. Z. Wang, and G. Ouyang Periostin: a bridge between cancer stem cells and their metastatic niche Cell Stem Cell 10 2012 111 112
17. R.S. Ismail, R.L. Baldwin, J. Fang, D. Browning, B.Y. Karlan, and J.C. Gasson et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells Cancer Res 60 2000 6744 6749
18. S. Cunat, P. Hoffmann, and P. Pujol Estrogens and epithelial ovarian cancer Gynecol Oncol 94 2004 25 32
19. W. Sieh, M. Kobel, T.A. Longacre, D.D. Bowtell, A. Defazio, and M.T. Goodman et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study Lancet Oncol 14 2013 853 862
20. H.P. Yang, W.F. Anderson, P.S. Rosenberg, B. Trabert, G.L. Gierach, and N. Wentzensen et al. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States J Clin Oncol 31 2013 2146 2151
21. A. Drilon, N. Rekhtman, M. Ladanyi, and P. Paik Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy Lancet Oncol 13 2012 e418 e426
22. U. McDermott, J.R. Downing, and M.R. Stratton Genomics and the continuum of cancer care N Engl J Med 364 2011 340 350
23. L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, and S. Taube et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 2007 5287 5312
24. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines Breast Cancer. Version 2.2011 2011 Available at: www.nccn.org. [Accessed September 11, 2013.]
25. D.R. Parkinson, B.E. Johnson, and G.W. Sledge Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics Clin Cancer Res 18 2012 619 624
26. A. Berchuck, E.S. Iversen, J.M. Lancaster, H.K. Dressman, M. West, and J.R. Nevins et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays Am J Obstet Gynecol 190 2004 910 925
27. Z.E. Selvanayagam, T.H. Cheung, N. Wei, R. Vittal, K.W. Lo, and W. Yeo et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling Cancer Genet Cytogenet 154 2004 63 66
28. M. Bernardini, C.H. Lee, B. Beheshti, M. Prasad, M. Albert, and P. Marrano et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer Neoplasia 7 2005 603 613
29. A.A. Jazaeri, C.S. Awtrey, G.V. Chandramouli, Y.E. Chuang, J. Khan, and C. Sotiriou et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers Clin Cancer Res 11 2005 6300 6310
30. D. Spentzos, D.A. Levine, S. Kolia, H. Otu, J. Boyd, and T.A. Libermann et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer J Clin Oncol 23 2005 7911 7918
31. J. Helleman, M.P. Jansen, P.N. Span, I.L. van Staveren, L.F. Massuger, and M.E. Meijer-van Gelder et al. Molecular profiling of platinum resistant ovarian cancer Int J Cancer 118 2006 1963 1971
32. L.C. Hartmann, K.H. Lu, G.P. Linette, W.A. Cliby, K.R. Kalli, and D. Gershenson et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy Clin Cancer Res 11 2005 2149 2155
33. A. Berchuck, E.S. Iversen, J.M. Lancaster, J. Pittman, J. Luo, and P. Lee et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers Clin Cancer Res 11 2005 3686 3696
34. D. Spentzos, D.A. Levine, M.F. Ramoni, M. Joseph, X. Gu, and J. Boyd et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer J Clin Oncol 22 2004 4700 4710
35. A.P. Crijns, R.S. Fehrmann, S. de Jong, F. Gerbens, G.J. Meersma, and H.G. Klip et al. Survival-related profile, pathways, and transcription factors in ovarian cancer PLoS Med 6 2009 e24
36. T. Bonome, D.A. Levine, J. Shih, M. Randonovich, C.A. Pise-Masison, and F. Bogomolniy et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer Cancer Res 68 2008 5478 5486
37. K. Yoshihara, A. Tajima, T. Yahata, S. Kodama, H. Fujiwara, and M. Suzuki et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets PLoS One 5 2010 e9615
38. C. Denkert, J. Budczies, S. Darb-Esfahani, B. Gyorffy, J. Sehouli, and D. Konsgen et al. A prognostic gene expression index in ovarian cancer - validation across different independent data sets J Pathol 218 2009 273 280
39. R.S. Fehrmann, X.Y. Li, A.G. van der Zee, S. de Jong, G.J. Te Meerman, and E.G. de Vries et al. Profiling studies in ovarian cancer: a review Oncologist 12 2007 960 966
40. K. Alsop, S. Fereday, C. Meldrum, A. deFazio, C. Emmanuel, and J. George et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J Clin Oncol 30 2012 2654 2663
41. K.N. Maxwell, and S.M. Domchek Cancer treatment according to BRCA1 and BRCA2 mutations Nat Rev Clin Oncol 9 2012 520 528
42. D. Matei, T.G. Graeber, R.L. Baldwin, B.Y. Karlan, J. Rao, and D.D. Chang Gene expression in epithelial ovarian carcinoma Oncogene 21 2002 6289 6298
43. M. Zhu, R.E. Saxton, L. Ramos, D.D. Chang, B.Y. Karlan, and J.C. Gasson et al. Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis Mol Cancer Ther 10 2011 1500 1508
44. R.G. Verhaak, P. Tamayo, J.Y. Yang, D. Hubbard, H. Zhang, and C.J. Creighton et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma J Clin Invest 123 2013 517 525
45. B. Hylander, E. Repasky, P. Shrikant, M. Intengan, A. Beck, and D. Driscoll et al. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer Gynecol Oncol 101 2006 12 17
46. F. Modugno, R. Laskey, A.L. Smith, C.L. Andersen, P. Haluska, and S. Oesterreich Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer 19 2012 R255 R279